NeuroPace to Host Investor Day on January 28th in New York City
NeuroPace to Host Investor Day on January 28th in New York City
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will host an Investor Day from 9:00 a.m. – 12:00 p.m. ET on Tuesday, January 28, 2025 in New York City.
加利福尼亞州山景城,2024年12月12日(環球新聞專線)——專注於改變癲癇患者生活的醫療器械公司NeuroPace, Inc.(納斯達克股票代碼:NPCE)今天宣佈,該公司將於美國東部時間2025年1月28日星期二上午9點至中午12點在紐約市舉辦投資者日。
The Investor Day will provide an update on NeuroPace's vision for its unique RNS technology and will highlight the Company's plans including presentations from management discussing NeuroPace's recent results, future plans, and market, product and clinical development strategies for the RNS System. The Company will also host guest speakers, including clinical key opinion leaders and an RNS patient who will provide their personal experience with the RNS System and its impact on their epilepsy.
投資者日將介紹NeuroPace對其獨特的RNS技術的最新願景,並將重點介紹該公司的計劃,包括管理層的演講,討論NeuroPace的近期業績、未來計劃以及RNS系統的市場、產品和臨床開發戰略。該公司還將邀請特邀演講嘉賓,包括臨床關鍵意見領袖和一名RNS患者,他們將提供他們對RNS系統的親身經歷及其對癲癇的影響。
Use the link below to register for the event:
使用以下鏈接註冊該活動:
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
關於 NeuroPace, Inc.
NeuroPace是一家醫療器械公司,總部位於加利福尼亞州山景城,致力於通過減少或消除使人衰弱的癲癇發作的發生來改變癲癇患者的生活。其新穎而差異化的RNS系統是第一個也是唯一一個在發作源頭提供個性化實時治療的市售大腦反應平台。該平台可以提高耐藥性癲癇患者的護理標準,並有可能爲大量患有其他腦部疾病的患者提供更加個性化的解決方案和更好的預後。
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
投資者聯繫方式:
傑里米·費弗
董事總經理
LifeSCI 顧問
jfeffer@lifesciadvisors.com